RecruitingPhase 2NCT06782373
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Studying VEXAS syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Study PhysicianSobi, Inc.
- Intervention
- Pacritinib(drug)
- Enrollment
- 78 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (20)
- Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
- University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- NYU Langone Health, New York, New York, United States
- Cleveland Clinic - Cleveland, Cleveland, Ohio, United States
- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
- University of Utah Healthcare, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada
- Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Hospital du Sacre-Coeur in Montreal, Montreal, Quebec, Canada
- Lille University Hospital Center, Lille, France
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06782373 on ClinicalTrials.govOther trials for VEXAS syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07102849Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research StudyNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE1NCT06538181Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeWashington University School of Medicine
- RECRUITINGNCT06657846HRQoL and Financial Toxicity in Patients With VEXAS SyndromeGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGNCT06377462Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial CollectionTechnische Universität Dresden